Boehringer Ingelheim Plans Biopharmaceuticals Facility in China - - BioPharm International

ADVERTISEMENT

Boehringer Ingelheim Plans Biopharmaceuticals Facility in China


Boehringer Ingelheim signed an alliance agreement and contract to build a cGMP biopharmaceuticals facility with Zhangjiang Biotech & Pharmaceutical Base Development Company (ZJ Base Company) in Pudong, Shanghai, the company announced in a press release. The new site will provide a full range of development and clinical services to Chinese and multinational customers. It will become the first facility established by a leading international biopharmaceuticals manufacturer in China using mammalian cell-culture technology, the company claimed.

The facility will include technical process development and cGMP manufacturing and will be ready for operation in early 2016.
 “Our partnership with ZJ Base Company is an important step in our global China strategy as it opens a further opportunity for Boehringer Ingelheim to participate in the growing demand for high-quality biopharmaceuticals in China,” stated Christian Boehringer, chairman of the Shareholders Committee, in the press release.

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Contract Research and Manufacturing Organization Paragon Bioservices Raises $13 Million
October 28, 2014
Yale and Gilead Extend Sequencing Initiative
October 28, 2014
Author Guidelines

Click here